EBPL inhibitors represent a chemical class designed to modulate the activity of the Emopamil Binding Protein-like (EBPL) enzyme, which is presumed to play a role in cellular processes linked to cholesterol and lipid metabolism. These inhibitors operate through various mechanisms to alter the function of EBPL, with a significant focus on the interception of cholesterol synthesis and related metabolic pathways. By targeting enzymes such as HMG-CoA reductase, a key catalyst in the mevalonate pathway responsible for the synthesis of cholesterol, these inhibitors can decrease the synthesis of cholesterol and its intermediates. This reduction in cholesterol biosynthesis can lead to a decreased availability of essential substrates and intermediates that EBPL might utilize or regulate, thereby inhibiting its function. Moreover, the binding of certain inhibitors to bile acids can modulate the internal cholesterol pool, exerting an influence on EBPL activity by shifting the balance of metabolic intermediates and substrates within the cell.
The chemical class of EBPL inhibitors encompasses molecules that interact with the cholesterol absorption process, affecting the overall cholesterol homeostasis within the cell. By reducing the absorption of cholesterol from the gastrointestinal tract, these inhibitors can alter the intracellular levels of cholesterol, which can, in turn, affect EBPL. In addition, some members of this class are known for their role in affecting lipid metabolism. By altering the availability of lipids, these inhibitors can influence the activity or stability of EBPL. Furthermore, the influence on lipid metabolism can extend to modifying the expression of EBPL, as the availability of lipid molecules can regulate the transcriptional activity of genes involved in lipid homeostasis and metabolism. The actions of EBPL inhibitors are not limited to a single biochemical pathway but rather encompass a network of metabolic interactions, each contributing to the regulation of EBPL's function within the cell.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Lovastatin inhibits HMG-CoA reductase. If EBPL is related to cholesterol synthesis or its regulation, lovastatin might decrease the availability of cholesterol intermediates, which could possibly inhibit EBPL's role or expression. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Simvastatin inhibits HMG-CoA reductase. By reducing cholesterol synthesis, it could possibly inhibit EBPL if the protein interacts with cholesterol or related metabolites. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Atorvastatin reduces cholesterol production by inhibiting HMG-CoA reductase. Reduced levels of cholesterol could possibly inhibit EBPL's activity if it is part of cholesterol metabolism. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $142.00 | 8 | |
By inhibiting HMG-CoA reductase, rosuvastatin could reduce cholesterol and its precursors, which could possibly inhibit EBPL's function if it interacts with these molecules. | ||||||
Fluvastatin | 93957-54-1 | sc-279169 | 50 mg | $250.00 | ||
Fluvastatin's effect on HMG-CoA reductase could lead to a reduction of EBPL's activity if EBPL is involved in the downstream products of the cholesterol synthesis pathway. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $73.00 $163.00 | 2 | |
Amlodipine may have secondary effects on cholesterol synthesis pathways, which could possibly inhibit EBPL if it has a role in cholesterol-dependent cellular processes. | ||||||
Ezetimibe | 163222-33-1 | sc-205690 sc-205690A | 25 mg 100 mg | $94.00 $236.00 | 12 | |
Ezetimibe reduces cholesterol absorption. This action could possibly inhibit EBPL if it is involved in cholesterol regulation. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $65.00 $262.00 | 2 | |
Gemfibrozil affects lipid metabolism. This could possibly inhibit EBPL if it is involved in this process, altering lipid availability and impacting EBPL's activity or expression. | ||||||